Takeda Pharmaceutical Profits Soar to 184.2 Billion Yen! Raises Full-Year Profit Forecast, Cost-Cutting Restructuring Plan
Takeda Pharmaceutical, Japan's largest drugmaker, reported second-quarter earnings on Thursday that beat market expectations. The company also raised its full-year earnings forecast. Takeda is currently undergoing a restructuring plan aimed at cutting costs and improving efficiency.
Takeda posted an operating profit of 184.2 billion yen ($1.21 billion) in the three months through September, compared with a loss of 49.3 billion yen a year earlier, when the company was in the red. According to a survey of four analysts by LSEG, Takeda's results far exceeded the consensus forecast of 93.6 billion yen in earnings.
Based on the strong first-half performance and an update to currency assumptions, Takeda raised its full-year operating profit forecast to 265 billion yen from 225 billion yen.
In May, Takeda announced it would restructure to improve margins and refocus on drug discovery. The company plans to cut or reposition about 1,200 employees at centers in San Diego and Massachusetts, according to domestic media reports, and last week unveiled an early retirement plan for employees in Japan.
While Takeda declined to give details on the specific positions affected, the company told Reuters that the restructuring was aimed at "maximizing the potential of our therapeutic portfolio, product lines and organizational structure for long-term growth."
Takeda is trying to rebuild its drug pipeline. Last year, the company suffered failures in clinical trials for lung cancer and Crohn's disease treatments, leading to large impairment losses. However, the company has high hopes for its experimental narcolepsy treatment TAK-861 and psoriasis candidates. The drugs were acquired by Takeda from Us-Based Nimbus Therapeutics in late 2022 for up to $6 billion.
While Takeda's shares are up 5.2% this year, that still underperforms the benchmark Nikkei average's 17% gain.
2026-10-21
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
“Hidden Champion” Swallowed Whole: PPG’s Acquisition of EMM Isn’t Just About Three Brands—It’s a Grab for the Next Decade’s Coating Authority
-
“Amputate to Survive, or Bleed to Feed the Vultures?”: Dow’s 4,500 Layoffs Reveal the Life-or-Death Battle in Global Chemicals
-
“Europe’s Chemical Industry Is Bleeding”: 37 Million Tons of Capacity Shut Down in 4 Years—Is the Industrial Heartbeat Failing?
-
Dafeng Haijianuo’s RMB 246 Million Technical Revamp Project Takes Shape, with Multiple Production Lines for Vitamin K1, Folic Acid, and Others Under Construction
-
BASF Approves €1 Billion Share Buyback Program as Chemical Giant Prioritizes Capital Discipline
-
INEOS Shuts Down Europe's Last World-Scale Acetyl Production Facilities
-
Evonik to Cut 3,200 Jobs Globally as Restructuring Deepens Across German Operations
-
BASF’s 2025 Report Card—“The Profit Evaporation Act”: Behind the €6.6 Billion EBITDA Lies a Deliberate Strategic Retreat
-
Univar Solutions Expands Partnership with American Distilling in EMEA to Strengthen Natural Specialty Ingredients Distribution Network
-
Wanhua Chemical’s “Tale of Two Cities”: 850,000 Tonnes Isn’t Capacity—It’s a Declaration of War
Recommend Reading
-
ContextLogic Acquires gChem for $850 Million in Major Specialty Chemicals Deal
-
$25 Billion Paint Giant Born: AkzoNobel and Axalta Shareholders Approve Merger by Landslide
-
Ashland Explores Sale as Private Equity Circles $4.5 Billion Specialty Chemicals Portfolio
-
Lenzing Group, a European fiber giant with over a century of history, is being forced to close two plants and cut 2,000 jobs globally
-
Evonik Reports Strong Q2 Results as Supply Chain Disruptions Boost Chemical Margins
-
Cost Values and Demand-Side Game: PP Prices Consolidate After Rising in July
-
Strong Supply and Weak Demand & Cost Regression: PC Prices First Decline Then Rise in July in China
-
Business Society Melamine Daily Report: Trend Clearly Upward on August 7, 2026; Fundamentals Provide Price Support
-
Business Society Melamine Daily Report: Stagnation Warning Issued for August 6, 2026!
-
Business Society Epoxy Resins Daily Report: Overall Stability on August 7, 2026
- Hot Searches
- buy 9-me-bc
- draw the structure of 3 4-dimethyl-1-pentene
- bulk acetic acid
- industrial carbon black pigment supplier
- acetic acid bulk
- menadione sodium bisulfite
- retatrutide vendor
- bioglutide for sale
- kalium oxide
- retatrutide peptide buy usa price
- buying testosterone enanthate
- reta for sale